Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1

F. Leoni, M. I. Colnaghi, S. Canevari, S. Menard, E. Colzani, P. Facheris, M. Figini, S. Miotti, J. L. Magnani

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The monoclonal antibody MLuC1, which reacts strongly with a high percentage of small-cell lung cancers (SCLC), as well as with various human carcinomas, has been used to immunochemically characterize the recognized epitope (CaMLuC1). To this aim 3 different approaches were adopted: (1) immunoblotting/immunostaining of extracts from various tumor-cell lines; (2) inhibition of binding by purified oligosaccharides; (3) direct binding to oligosaccharide-protein conjugates. All of these experiments indicate that CaMLuC1 is present on the Le(y) blood-group structure heterogeneously expressed on various glycoproteins and glycolipids. The expression of the glycoconjugates carrying Le(y) was then analyzed on breast and lung cancers and on their normal counterparts. Our overall results suggest that SCLC produce Le(y)-active glycolipids in higher amounts compared to other tumors of the same or of a different oncotype, as well as normal lung cells, thus indicating an SCLC-specific modification of the glycosylation pathways.

Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalInternational Journal of Cancer
Volume51
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Glycolipids
Small Cell Lung Carcinoma
Monoclonal Antibodies
Oligosaccharides
Glycoconjugates
Blood Group Antigens
Tumor Cell Line
Glycosylation
Immunoblotting
Epitopes
Lung Neoplasms
Glycoproteins
Breast Neoplasms
Carcinoma
Lung
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. / Leoni, F.; Colnaghi, M. I.; Canevari, S.; Menard, S.; Colzani, E.; Facheris, P.; Figini, M.; Miotti, S.; Magnani, J. L.

In: International Journal of Cancer, Vol. 51, No. 2, 1992, p. 225-231.

Research output: Contribution to journalArticle

Leoni, F. ; Colnaghi, M. I. ; Canevari, S. ; Menard, S. ; Colzani, E. ; Facheris, P. ; Figini, M. ; Miotti, S. ; Magnani, J. L. / Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. In: International Journal of Cancer. 1992 ; Vol. 51, No. 2. pp. 225-231.
@article{c010e7d4970a4732adfaad3118f8fa99,
title = "Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1",
abstract = "The monoclonal antibody MLuC1, which reacts strongly with a high percentage of small-cell lung cancers (SCLC), as well as with various human carcinomas, has been used to immunochemically characterize the recognized epitope (CaMLuC1). To this aim 3 different approaches were adopted: (1) immunoblotting/immunostaining of extracts from various tumor-cell lines; (2) inhibition of binding by purified oligosaccharides; (3) direct binding to oligosaccharide-protein conjugates. All of these experiments indicate that CaMLuC1 is present on the Le(y) blood-group structure heterogeneously expressed on various glycoproteins and glycolipids. The expression of the glycoconjugates carrying Le(y) was then analyzed on breast and lung cancers and on their normal counterparts. Our overall results suggest that SCLC produce Le(y)-active glycolipids in higher amounts compared to other tumors of the same or of a different oncotype, as well as normal lung cells, thus indicating an SCLC-specific modification of the glycosylation pathways.",
author = "F. Leoni and Colnaghi, {M. I.} and S. Canevari and S. Menard and E. Colzani and P. Facheris and M. Figini and S. Miotti and Magnani, {J. L.}",
year = "1992",
doi = "10.1002/ijc.2910510210",
language = "English",
volume = "51",
pages = "225--231",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1

AU - Leoni, F.

AU - Colnaghi, M. I.

AU - Canevari, S.

AU - Menard, S.

AU - Colzani, E.

AU - Facheris, P.

AU - Figini, M.

AU - Miotti, S.

AU - Magnani, J. L.

PY - 1992

Y1 - 1992

N2 - The monoclonal antibody MLuC1, which reacts strongly with a high percentage of small-cell lung cancers (SCLC), as well as with various human carcinomas, has been used to immunochemically characterize the recognized epitope (CaMLuC1). To this aim 3 different approaches were adopted: (1) immunoblotting/immunostaining of extracts from various tumor-cell lines; (2) inhibition of binding by purified oligosaccharides; (3) direct binding to oligosaccharide-protein conjugates. All of these experiments indicate that CaMLuC1 is present on the Le(y) blood-group structure heterogeneously expressed on various glycoproteins and glycolipids. The expression of the glycoconjugates carrying Le(y) was then analyzed on breast and lung cancers and on their normal counterparts. Our overall results suggest that SCLC produce Le(y)-active glycolipids in higher amounts compared to other tumors of the same or of a different oncotype, as well as normal lung cells, thus indicating an SCLC-specific modification of the glycosylation pathways.

AB - The monoclonal antibody MLuC1, which reacts strongly with a high percentage of small-cell lung cancers (SCLC), as well as with various human carcinomas, has been used to immunochemically characterize the recognized epitope (CaMLuC1). To this aim 3 different approaches were adopted: (1) immunoblotting/immunostaining of extracts from various tumor-cell lines; (2) inhibition of binding by purified oligosaccharides; (3) direct binding to oligosaccharide-protein conjugates. All of these experiments indicate that CaMLuC1 is present on the Le(y) blood-group structure heterogeneously expressed on various glycoproteins and glycolipids. The expression of the glycoconjugates carrying Le(y) was then analyzed on breast and lung cancers and on their normal counterparts. Our overall results suggest that SCLC produce Le(y)-active glycolipids in higher amounts compared to other tumors of the same or of a different oncotype, as well as normal lung cells, thus indicating an SCLC-specific modification of the glycosylation pathways.

UR - http://www.scopus.com/inward/record.url?scp=0026576273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026576273&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910510210

DO - 10.1002/ijc.2910510210

M3 - Article

C2 - 1373704

AN - SCOPUS:0026576273

VL - 51

SP - 225

EP - 231

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -